ARTV advances pivotal Phase III trial for refractory RA
ARTV’s AlloNK cell platform is advancing in a pivotal Phase III trial for refractory RA. Enrollment is robust, with data updates expected by year-end and top-line results targeted for 2028.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.